Context Therapeutics Inc.

NASDAQ:CNTX

Biotechnology

Healthcare
$0.69 +2.93%

+$0.02 today

Market cap
$63.67M
Beta
1.61
P/E (TTM)
-1.5
EPS (TTM)
-$0.42
52W Low $0.56High $3.62

Volume 1.71M

Average 1.16M

CNTX Total Debt

Short-term and long-term borrowings combined.

Context Therapeutics Inc.NASDAQ: CNTX

Total Debt · Q1 FY2026 · quarter ended Mar 2026

Total debt rises 45.8% from a year ago

Total debt stood at $282.42K at the end of Q1 FY2026, up 45.8% from a year earlier and up 152.0% from the prior quarter. Over 3 fiscal years it compounded at +26.7% a year.

Context

  • Total debt amounted to 0.5% of total assets at the end of Q1 FY2026, up 0.3 pp from a year earlier.
  • Total debt increased in 1 of the last 3 fiscal years.

What to watch

Whether total debt keeps rising in the next quarterly balance sheet after a +45.8% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$282.42K+152.0% QoQ
Last fiscal yearDec 2025
$112.06K-48.9% YoY
Year agoMar 2025
$193.71K+45.8% since
Total Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+45.8%——
1 year-48.9%——
3-year CAGR+26.7%——
5-year CAGR——
10-year CAGR——

Total Debt history

USD · from the balance sheet

Latest · FY2025
112.06K USD
Year-over-year change
-48.9%

Total Debt vs competitors

How CNTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so total debt is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +45.8% is the 3rd highest of 9, against a peer median of +11.3%.
  • Total debt amounts to 0.5% of total assets for CNTX, versus a peer median of 1.5%.
CNTX Competitors
Total Debt for CNTX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
MGNXMacroGenics, Inc.Mar 2026$36.51M USD-2.6%+45.3%16.8%
CLNNClene Inc.Mar 2026$22.05M USD+5.3%-12.0%101.8%
IMAImageneBio IncMar 2026$8.15M USD+23.2%+20.6%6.0%
STTKShattuck Labs, Inc.Mar 2026$2.89M USD-9.5%-21.0%2.8%
OVIDOvid Therapeutics Inc.Mar 2026$1.46M USD-89.9%-6.7%0.6%
KLRSKalaris Therapeutics IncMar 2026$1.41M USD—-23.6%1.3%
IFRXInflaRx N.V.Mar 2026€823.89K EUR+17.3%-12.9%1.7%
ORMPOramed Pharmaceuticals Inc.Mar 2026$761K USD+152.8%-2.6%0.3%
CNTBConnect Biopharma Holdings LimitedDec 2025$690K USD+287.6%+17.0%1.2%
CNTXContext Therapeutics Inc.Mar 2026$282.42K USD+45.8%+26.7%0.5%
WHWKWhitehawk Therapeutics IncMar 2026$0 USD——0.0%
Peer median (excluding CNTX) —+11.3%-6.7%1.5%

Competitors are the stored peer set for CNTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents49.64M35.5M14.45M94.43M66M
Short-term Investments00000
Net Receivables00000
Inventory00000
Other Current Assets(0)2.36M1.6M3.47M2.36M
Total Current Assets51.26M37.85M16.05M97.9M68.35M
Property, Plant & Equipment (Net)079.54K15.52K230.78K140.07K
Goodwill00000
Intangible Assets00000
Long-term Investments50.39K0000
Tax Assets00000
Other Non-current Assets032.75K000
Total Non-current Assets50.39K112.29K15.52K230.78K140.07K
Total Assets51.31M37.97M16.06M98.13M68.49M
Account Payables1.83M936.33K2.38M1.45M2.53M
Short-term Debt00000
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities85.53K853.51K661.3K941.7K1.42M
Total Current Liabilities3.03M3.21M4.19M2.75M8.02M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities00000
Total Non-current Liabilities000112.06K0
Total Liabilities3.03M3.21M4.19M2.86M8.02M
Common Stock15.97K15.97K15.97K89.7K91.88K
Retained Earnings(29.25M)(44.09M)(68.05M)(94.78M)(130.9M)
Accumulated OCI00000
Other Stockholders Equity00000
Minority Interest00000
Total Equity48.27M34.76M11.87M95.27M60.47M
Total Debt055.08K0219.38K112.06K
Net Debt(49.64M)(35.44M)(14.45M)(94.21M)(65.88M)

Context Therapeutics Inc.

NASDAQ:CNTX

Intrinsic Alpha fair value

Locked

Current Price

$0.69

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.